MONTREAL, QUEBEC--(Marketwire - November 29, 2007) - Thallion Pharmaceuticals Inc. (TSX: TLN) today announced that it presented data from a brain tumour model demonstrating that ECO-4601 crosses the blood brain barrier and preferentially targets and accumulates in glioblastoma (brain) tumours. These data also show that ECO-4601 binds in vivo to the peripheral benzodiazepine receptor (PBR), a receptor that is highly expressed in numerous cancer types, including glioblastoma.
